Governance Cellectis S.A.

ALCLS

FR0010425595

Biotechnology & Medical Research

Market Closed - Euronext Paris Other stock markets 16:55:00 13/05/2026 BST			5-day change	1st Jan Change
3.548 ^EUR	+3.32%		+7.00%	-15.42%

05-12	European Equities Traded in the US as American Depositary Receipts Decline Sharply in Tuesday Trading	MT
05-12	Atos, Fnac Darty, Chargeurs... stocks to watch today in Paris

Executive Committee: Cellectis S.A.

Manager

Positions heldSince

André Choulika

61 year

Chief Executive Officer	19/12/1999
Founder	19/12/1999

Arthur Stril

37 year

Director of Finance/CFO	01/05/2024
Investor Relations Contact	30/06/2018

Adrian Kilcoyne

56 year

Chief Tech/Sci/R&D Officer

06/08/2024

Kyung Nam-Wortman

56 year

Human Resources Officer

15/11/2020

Philippe Duchateau

63 year

Chief Tech/Sci/R&D Officer

31/03/2001

Stephan Reynier

57 year

Compliance Officer	31/03/2011
General Counsel	31/03/2011

Marie-Bleuenn Terrier

44 year

General Counsel	31/12/2007
Corporate Secretary	31/12/2014

Composition of the Board of Directors: Cellectis S.A.

Director

CommitteesSince

Jean-Pierre Garnier

77 year

Compensation Committee	19/08/2024
Governance Committee	19/08/2024
Nominating Committee	19/08/2024

Laurent Arthaud

63 year

Audit Committee
Finance Committee

Rainer Boehm

65 year

Audit Committee	31/08/2022
Compensation Committee	31/08/2022

André Choulika

61 year

Audit Committee	31/05/2019
Finance Committee	31/05/2019

André Muller

62 year

Audit Committee Chair

25/06/2025

Donald Bergstrom

54 year

Audit Committee

25/06/2025

Tyrell J. Rivers

53 year

Audit Committee

31/05/2018

Cécile Chartier

59 year

Director/Board Member

26/06/2023

Marc Dunoyer

73 year

Director/Board Member

05/05/2024

David Sourdive

59 year

Director/Board Member

31/12/1999

Latest Appointments: Cellectis S.A.

03-12	Poolbeg Pharma plc Appoints Adrian Kilcoyne to Scientific Advisory Board	CI
11-13	Cellectis S.A. Announces Board Appointments	CI
26/06/25	Cellectis S.A. Announces Board Changes	CI
21/05/25	Cellectis S.A. Announces Resignation of Pierre Bastid from the Board of Directors, Effective June 26, 2025	CI
07/08/24	France's Cellectis Names New Chief Medical Officer	MT
07/08/24	Cellectis S.A. Announces Executive Changes	CI
07/08/24	Cellectis appoints new Medical Director

More news

Former Officers and Directors: Cellectis S.A.

Insider

Positions held

SinceUntil

Axel-Sven Malkomes

Director/Board Member	27/06/2022	25/06/2025
Independent Dir/Board Member	27/06/2022	25/06/2025

Pierre Bastid

Director/Board Member	27/10/2011	25/06/2025
Independent Dir/Board Member	27/10/2011	25/06/2025

Mark Frattini

Chief Tech/Sci/R&D Officer	27/09/2022	06/08/2024
Corporate Officer/Principal	31/07/2020	27/09/2022

Bing Wang

Director of Finance/CFO

09/02/2022

01/05/2024

Herve Hoppenot

Director/Board Member	28/06/2017	26/06/2023
Independent Dir/Board Member	28/06/2017	26/06/2023

Annick Schwebig

Director/Board Member	27/10/2011	26/06/2023
Independent Dir/Board Member	27/10/2011	26/06/2023

Margaret Gandolfo

Public Communications Contact

31/01/2023

Alain Munoz

Director/Board Member

30/12/2022

Carrie Brownstein

Chief Tech/Sci/R&D Officer

12/04/2020

27/09/2022

Simon Harnest

Chief Investment Officer	31/03/2015	31/05/2021
Investor Relations Contact	31/03/2015	31/05/2021
Corporate Officer/Principal	-	-

William Monteith

Corporate Officer/Principal

09/12/2018

05/08/2020

Léopold Bertea

Corporate Officer/Principal

17/05/2020

Francisco J. Esteva

Chief Tech/Sci/R&D Officer

05/11/2019

Elsy Boglioli Hofman

Chief Operating Officer	13/03/2018	31/07/2019
Corporate Officer/Principal	04/12/2017	13/03/2018

Stephane Depil

Chief Tech/Sci/R&D Officer

03/12/2017

31/01/2019

Stefan J. Scherer

Corporate Officer/Principal

02/08/2018

31/01/2019

Mathieu Simon

Director/Board Member	13/06/2013	10/10/2017
Chief Operating Officer	31/12/2012	13/03/2018
Chief Tech/Sci/R&D Officer	04/10/2017	13/03/2018
Corporate Officer/Principal	31/12/2011	13/06/2013

Loan Hoang-Sayag

Chief Tech/Sci/R&D Officer

07/01/2016

04/10/2017

Eric Dutang

Director of Finance/CFO

30/04/2015

Jean-Marie Messier

Director/Board Member	30/04/2015	-
Independent Dir/Board Member	30/04/2015	-

Thierry Moulin

Director of Finance/CFO	31/12/2013	-
Investor Relations Contact	31/12/2013	-

Marc Le Bozec

Director of Finance/CFO	30/09/2006	24/02/2013
Investor Relations Contact	30/09/2006	24/02/2013
Public Communications Contact	30/09/2006	24/02/2013

Frédéric Cédrone

Corporate Officer/Principal

29/01/2012

Frédéric Pâques

Chief Tech/Sci/R&D Officer

30/09/2001

29/01/2012

Philippe Valachs

Corporate Secretary

23/10/2011

Dirk Pollet

Corporate Officer/Principal

27/05/2010

31/05/2011

Pierre Schwich

Director of Finance/CFO

24/02/2013

Luc Mathis

Corporate Officer/Principal

31/12/2005

30/11/2010

Julia Berretta

Corporate Officer/Principal

31/12/2013

Sylvie Delassus

Public Communications Contact

27/05/2010

Alain Godard

Director/Board Member	30/09/2007	-
Independent Dir/Board Member	30/09/2007	-

Aymeric Duclert

Chief Tech/Sci/R&D Officer

27/05/2010

Delphine Jay

Chief Administrative Officer	31/12/2000	-
Human Resources Officer	27/05/2010	-

Isabelle Pelletier-Bressac

Corporate Officer/Principal

30/09/2000

Jean-Charles Epinat

Chief Tech/Sci/R&D Officer	02/02/2012	-
Corporate Officer/Principal	27/05/2010	02/02/2012

Laure Ory-Lavollée

Director/Board Member

Roger Hajjar

Director/Board Member

27/05/2010

Martin Bitsch

Director/Board Member

Raffy Kazandjian

Director/Board Member

Georges Rawadi

Corporate Officer/Principal

Christian Policard

Chairman

Bruno Brisson

Corporate Officer/Principal

Richard Mulligan

Director/Board Member

27/05/2010

Victor Chaulot-Talmon

Investor Relations Contact

Thomas Tscherning

Director/Board Member

François Hyafil

Director/Board Member

Age distribution of managers

Parity Men Women

Male	16
Female	2

Of which Executive Committee

Male	5
Female	2

Of which Directors

Male	10
Female	0

Cellectis S.A. is a clinical-stage biotechnology company using its pioneering TALEN® genome-editing technology to develop innovative therapies for the treatment of serious diseases. Cellectis S.A. is developing the first CAR T cell-based allogeneic immunotherapy therapeutics, inventing the concept of off-the-shelf, ready-to-use engineered CAR T cells for the treatment of cancer patients, and a platform for for the development of gene therapies in other therapeutic indications. Thanks to its fully in-house production capabilities, Cellectis S.A. is one of the few genome-editing companies to control the cell and gene therapy value chain from end to end.

Employees

227

Sector

Biotechnology & Medical Research

More about the company